COO vs OGN
COO: A global medical device leader operating at the intersection of vision care and women's health through its CooperVision and CooperSurgical divisions. OGN: A diversified pharmaceutical company spun from Merck focusing on established branded medicines and medical devices for women's health, infectious disease, and other therapeutic areas.
Side-by-side fundamentals
| Metric | COO | OGN | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $70.29 | $13.54 | |
| Market cap as of 2026-07-30 | $14.1B | $3.6B | |
| P/E as of 2026-07-30 | 59.70 | 14.45 | OGN lower |
| PEG as of 2026-07-30 | 6.73 | 2.14 | OGN lower |
| Net margin as of 2026-07-30 | +5.6% | +4.0% | COO higher |
| Gross margin as of 2026-07-30 | +65.5% | +52.8% | COO higher |
| Operating margin as of 2026-07-30 | +11.8% | +8.7% | COO higher |
| ROE as of 2026-07-30 | +2.8% | +29.9% | OGN higher |
| ROA as of 2026-07-30 | +1.9% | +1.9% | COO higher |
| Debt / equity as of 2026-07-30 | 0.30 | 9.49 | COO lower |
| Revenue growth (YoY) as of 2026-07-30 | +6.1% | -2.1% | COO higher |
| Revenue CAGR (3y) SEC XBRL | +7.3% | +0.2% | COO higher |
| Dividend yield as of 2026-07-30 | +0.0% | +0.6% | OGN higher |
| Dividend streak (yrs) SEC XBRL | 5 | 1 | COO higher |
| Beta as of 2026-07-30 | 0.82 | 1.52 | |
| 1-year return as of 2026-07-27 close | -5.8% | +32.6% | OGN higher |
Fundamentals: market data, as of 2026-07-30. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.